An analyst thinks Palantir will see AI benefits but deems the stock’s valuation to be steep on a relative basis and given industry pressures.
The offering is aimed at boosting liquidity and paying down part of a $2 billion revolving-credit facility.
“Just because market value is transferring quickly, doesn’t make it wrong,” an analyst says.
‘Active-adult’ communities are attracting younger buyers who are looking closer to home
What Pamela Teaster really wants to be is a paramedic, and she’ll think about retirement when she hits triple digits.
Oil futures ticked lower Friday, but remained on track for solid weekly gains as investors gauged the potential for a wider Middle Eastern conflict that could endanger crude flows from the region.
CarMax reported lower sales, but the company is encouraged by more affordable prices.
Sarapeta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
